HUTCHMED (China) Limited logo

HUTCHMED (China) LimitedNASDAQ: HCM

Profile

Sector:

Healthcare

Country:

Hong Kong

IPO:

16 March 2016

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.97 B
-51%vs. 3y high
85%vs. sector
-vs. 3y high
-vs. sector
-35%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 19 min ago
$17.38-$0.30(-1.70%)

Dividend

No data over the past 3 years
$433.20 M$433.20 M
No data over the past 3 years

Analysts recommendations

Institutional Ownership

HCM Latest News

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
globenewswire.com21 November 2024 Sentiment: POSITIVE

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZAQLA® (fruquintinib) 1mg/5mg capsules in Japan by its partner Takeda (TSE:4502/​NYSE:TAK) for patients with previously treated metastatic colorectal cancer (“CRC”).

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
globenewswire.com20 November 2024 Sentiment: POSITIVE

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024.

Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
globenewswire.com08 November 2024 Sentiment: NEGATIVE

SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
globenewswire.com05 November 2024 Sentiment: POSITIVE

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by HUTCHMED will be presented at the American Society of Hematology (“ASH”) Annual Meeting taking place on December 7-10, 2024 in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Asia Congress 2024, taking place on December 6-8, 2024 in Singapore.

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
globenewswire.com31 October 2024 Sentiment: POSITIVE

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — — US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
globenewswire.com17 October 2024 Sentiment: POSITIVE

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
globenewswire.com16 October 2024 Sentiment: POSITIVE

— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer —

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
globenewswire.com27 September 2024 Sentiment: POSITIVE

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon's novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
globenewswire.com24 September 2024 Sentiment: POSITIVE

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer —

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
businesswire.com17 September 2024 Sentiment: POSITIVE

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The team will be joined by CIRRUS-HCM investigator, Anjali T. Owens, M.D.,.

  • 1(current)
  • 2

What type of business is HUTCHMED (China) Limited?

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

What sector is HUTCHMED (China) Limited in?

HUTCHMED (China) Limited is in the Healthcare sector

What industry is HUTCHMED (China) Limited in?

HUTCHMED (China) Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is HUTCHMED (China) Limited from?

HUTCHMED (China) Limited is headquartered in Hong Kong

When did HUTCHMED (China) Limited go public?

HUTCHMED (China) Limited initial public offering (IPO) was on 16 March 2016

What is HUTCHMED (China) Limited website?

https://www.hutch-med.com

Is HUTCHMED (China) Limited in the S&P 500?

No, HUTCHMED (China) Limited is not included in the S&P 500 index

Is HUTCHMED (China) Limited in the NASDAQ 100?

No, HUTCHMED (China) Limited is not included in the NASDAQ 100 index

Is HUTCHMED (China) Limited in the Dow Jones?

No, HUTCHMED (China) Limited is not included in the Dow Jones index

When was HUTCHMED (China) Limited the previous earnings report?

No data

When does HUTCHMED (China) Limited earnings report?

The next expected earnings date for HUTCHMED (China) Limited is 28 February 2025